The Alzheimer’s prevention protocol: What the FINGER trial and its successors actually showed

Why Alzheimer’s drug trials keep failing and what that tells us about prevention

The history of Alzheimer’s drug development is a long list of late-stage trial failures that cleared amyloid beautifully and moved the cognitive decline needle almost imperceptibly. The recently approved anti-amyloid antibodies (lecanemab, donanemab) modestly slow decline in early-stage disease but do not prevent it or reverse established cognitive loss. The consistent lesson from this failure pattern: once clinical Alzheimer’s disease is established, the pathological burden has exceeded what amyloid clearance alone can address. The disease is not just amyloid plaques. It is amyloid plaques plus tau tangles plus neuroinflammation plus synaptic loss plus neuronal death that has already occurred.

The prevention evidence is a different story entirely. The 2020 Lancet Commission identified twelve modifiable risk factors (expanded to 14 in 2024) that together account for 45 percent of dementia cases. These include hearing loss, hypertension, excessive alcohol, obesity, smoking, depression, physical inactivity, social isolation, traumatic brain injury, air pollution, diabetes, insufficient education, vision loss, and elevated LDL cholesterol. Each of these is addressable. Collectively, optimal management of all fourteen factors would prevent or substantially delay almost half of all dementia cases without any pharmaceutical intervention.

The FINGER trial in detail

The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) enrolled 1,260 adults aged 60 to 77 with elevated dementia risk (based on cardiovascular risk factors, lifestyle, and cognitive performance). Participants were randomized to a multimodal intervention or health advice control.

The intervention group received: individual dietary guidance toward a modified Nordic healthy diet; supervised aerobic and resistance exercise sessions three times per week; cognitive training in groups with computer-based exercises and strategy training; and intensive management of vascular risk factors (blood pressure, cholesterol, glucose, weight). Over two years, the intervention group showed 25 percent better performance on a comprehensive neuropsychological battery than controls, with the greatest benefits in executive function, processing speed, and complex memory tasks. At seven-year follow-up, the survival analyses showed the intervention group had significantly lower rates of dementia diagnosis.

The Livium recipe

Tool. The CAIDE (Cardiovascular Risk Factors, Aging and Dementia) score estimates 20-year dementia risk based on age, sex, education, systolic blood pressure, BMI, total cholesterol, and physical activity. It is the risk calculator used to select FINGER trial participants and provides a structured starting point for understanding personal dementia risk. A full cognitive baseline test on Cambridge Brain Sciences or CNS Vital Signs provides the pre-intervention cognitive performance reference.

Behavior. The self-directed FINGER protocol: Mediterranean-MIND dietary pattern (covered in the cognitive reserve article in this library); 150 minutes Zone 2 aerobic exercise plus two resistance sessions weekly; one genuinely new cognitive challenge weekly requiring learning rather than rehearsal; blood pressure below 130/80, fasting glucose below 100, hs-CRP below 1.0, sleep seven to nine hours nightly. These four pillars implemented simultaneously produce the most consistent prevention benefit in the evidence; single-pillar approaches produce smaller and less durable effects.

Threshold. Annual neuropsychological testing tracks cognitive trajectory. Stable or improving performance on a validated battery over three to five years in a midlife adult with known risk factors is a meaningful marker of the prevention protocol working. The biomarker targets (blood pressure, glucose, hs-CRP, sleep quality) provide ongoing feedback on the vascular risk management pillar.

Life Extension Cognitex Elite Pregnenolone provides phosphatidylserine, GPC, uridine, and pregnenolone in a formula supporting the cholinergic, glutamatergic, and neurosteroid systems most impaired in Alzheimer’s disease pathogenesis. NOW Foods Phosphatidyl Serine 150 mg is the most directly evidence-supported individual nootropic for Alzheimer’s prevention, with FDA-qualified health claim status for cognitive decline reduction and multiple published RCTs showing benefit in at-risk populations. Pure Encapsulations Bacopa has published evidence of improved memory consolidation and reduced beta-amyloid aggregation in preclinical models, with human trials showing improvements in working memory and cognitive processing speed over 12 weeks. NOW Foods Lion’s Mane provides the compounds hericenone and erinacine, which stimulate nerve growth factor (NGF) synthesis, supporting hippocampal neuroplasticity and neuronal maintenance through a mechanism complementary to the effects of phosphatidylserine and bacopa.

Selected factors only. PAF = population attributable fraction. Source: Livium editorial synthesis based on Livingston et al., The Lancet (2024), Dementia Prevention Commission.

Plan of action

• Check blood pressure this week if it has not been checked in the past year. Hypertension is the highest-yield modifiable risk factor for midlife dementia prevention, and the most commonly uncontrolled one. Target below 130/80.
• Get a hearing test if there is any sense of hearing difficulty, tinnitus, or asking people to repeat themselves. Hearing loss is the single largest population-attributable fraction for dementia among the 14 factors. Treating it with hearing aids reduces the social isolation and cognitive demand that untreated hearing loss produces.
• Implement the FINGER four-pillar protocol this month. Not sequentially. Simultaneously. The trial evidence is for the multimodal combination, not for any single pillar. Each pillar produces independent effects through different mechanisms; the combination is additive.
• Take baseline cognitive testing on Cambridge Brain Sciences and retest annually. The trajectory matters more than any single score, and the 10 to 15-year advance warning window that declining trajectory provides is where intervention is most effective.